Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a mutated p53 system, b) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control, e) a deregulated immediate early gene response, f) a canalicular network MATRIGEL.TM.

Abstract: The subject invention encompasses methods and compositions comprising N-acetylated amino acid complexes for reducing or preventing dental plaque, calculus, or gingival or periodontol diseases of the oral cavity in humans or lower animals.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: a) a normal p53 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; b) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; c) a normal c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; d) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; e) a normal immediate early gene response following mitogenic stimulation; f) a canalicular Matrigel growth pattern; g) non-tumorigenic in congenitally athymic mice; h) high levels of alkaline phosphatase activity; i) a lack of autocrine growth factor production; and j) an ability to be serially propagated greater than sixty population doublings.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma cell line has the following characteristics: a) a non-expressed p53 protein; b) a normal RB-1 gene; c) a 1O.times. amplified c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor; and an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a normal p53 gene; b) a normal RB-1 gene; c) a normal c-myc gene; d) a normal c-fos gene; e) a deregulated immediate early gene response; f) a canalicular network MATRIGEL.TM. growth pattern; g) poorly tumorigenic in congenitally athymic mice; h) no alkaline phosphatase activity; i) an ability to produce one or more of the following growth factors: 1) a non-heparin binding growth factor, 2) a first heparin binding growth factor, 3) a second heparin binding growth factor, and 4) a third heparin binding growth factor; and j) an ability to be serially propagated greater than sixty population doublings.The present invention also relates to growth factors having the characteristics of growth factors isolated from the rat osteosarcoma cell line.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma having the following characteristics: A) a non-expressed p53 protein; B) a normal RB-1 gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; C) a normal c-fos gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; D) a 50-fold amplified c-myc gene as compared to a non-tumorigenic Sprague-Dawley rat cell control; E) a monolayer MATRIGEL.TM. growth pattern; F) tumorigenic in nude mice; G) normal alkaline phosphatase activity; H) an ability to be serially propagated greater than fifty population doublings; I) an ability to produce a growth factor selected from the group consisting of: 1) a mesenchymal inhibitory growth factor; 2) a non-heparin binding mitogenic growth factor; 3) a first heparin binding mitogenic growth factor; 4) a second heparin binding mitogenic growth factor; 5) a third heparin binding mitogenic growth factor; and 6) a fourth heparin binding mitogenic growth factor.

Abstract: The subject invention relates to compositions in dosage form comprising a solid dispersion which is a solidified melt mixture consisting essentially of the following components:(a) from about 15% to about 75% of tebufelone;(b) from about 25% to about 65% of a poloxamer surfactant having a melting point of about 40.degree. C. or greater, the poloxamer surfactant consisting essentially of a block copolymer having three polymer blocks, a middle block of poly(oxypropylene) with a molecular weight of from about 1450 daltons to about 6000 daltons, and end blocks of poly(oxyethylene), the end blocks being from about 50% to about 90% of the copolymer; and(c) from 0% to about 60% of other components, wherein the other components are miscible with a melt mixture of components (a) and (b).

Abstract: The subject invention involves compositions comprising 4-(3,5-bis(1,1-dimethylethyl-4-hydroxyphenyl)-4-oxobutanamide, or 4-(3,5-bis-(1,1-dimethylethyl)-4-hydroxyphenyl)-4-oxobutanoic acid and pharmaceutically-acceptable salts thereof, and a pharmaceutically-acceptable carrier. The subject invention also involves methods for treating diseases characterized by inflammation and/or pain, such as rheumatoid arthritis and osteoarthritis, in humans or lower animals by administration of a safe and effective amount of this compound to the human or lower animal in need of such treatment.

Abstract: The present invention relates to a novel cell line isolated from a rat osteosarcoma wherein the cell line has the following characteristics: a) a mutated p53 gene incapable of expressing p53 protein, b) a normal RB-1 gene, c) a 10-fold amplified c-myc gene, d) a normal c-fos gene, e) a deregulated immediate early gene response, f) a canalicular network MATRIGEL.TM. growth pattern, g) tumorigenic in congenitally athymic mice, h) no alkaline phosphatase activity, i) an ability to produce one or more growth factors selected from the group consisting of: 1) an osteoblastic differentiation growth factor, 2) a non-heparin binding mitogenic growth factor, 3) a first heparin binding mitogenic growth factor, 4) a second heparin binding mitogenic growth factor, and 5) a third heparin binding mitogenic growth factor, and j) an ability to be serially propagated greater than sixty population doublings.

Abstract: The present invention relates to a composition for regulating hair growth comprising a safe and effective amount of the tripeptide histidyl-glycyl-glycine, or a derivative thereof, and a pharmaceutically-acceptable carrier.

Abstract: The present invention relates to novel chromophore-containing compounds useful as sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. These compounds comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are directly coupled to thereby form a new chromophore.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: The present invention relates to novel chromophore-containing compounds useful as sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. These compounds comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are directly coupled to thereby form a new chromophore.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: The present invention relates to novel sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. The sunscreen agents comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are not directly coupled.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans of lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: The present invention relates to novel chromophore-containing compounds useful as sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. These compounds comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are directly coupled to thereby form a new chromophore.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: The subject invention relates to methods for providing mucosal-protection comprising administering to a human or lower animal a safe and effective amount of an extract from plant species of the genera Wedelia, Eclipta and Aspilia.

Abstract: The subject invention relates to a process for the preparation of 2-alkyl-4-acyl-6-tert-butylphenol compound having the chemical structure: ##STR1## wherein -R is an aliphatic group having a terminally unsaturated moiety selected from --C.tbd.CH and --CH.dbd.C.dbd.CH.sub.2, and R' is selected from saturated, straight, branched or cyclic alkyl having from 1 to about 10 carbon atoms; the 2-alkyl-4-acyl-6-tert-butylphenol compound being produced in a reaction mixture comprising the corresponding 2-alkyl-6-tert-butylphenol: ##STR2## the corresponding carboxylic acid: RCOOH, and trifluoroacetic anhydride.

Abstract: The subject invention involves pharmaceutical compositions comprising a sulfated glyceroglucolipid having the structure: ##STR1## wherein n is an integer of from 1 to about 5, R is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, R' is hydrogen or C.sub.1 -C.sub.24 acyl or alkyl, and M.sup.+ is a cationic moiety, and methods of treating or preventing gastroduodenal diseases or disorders caused by or associated with H. pylori by administering such compounds.